A lateral flow assay (LFA) is a rapid chromatographic test method. It does not require infrastructure or equipment and is therefore suitable for use in many applications as a point‑of‑care test (POCT). Chemical or immunological LFAs exist for some time, the best‑known being the pregnancy test. However, there is still need for development of nucleic acid-based detection methods in LFAs (NALFAs), which could pave the way for the molecular detection of pathogens at the point‑of‑care. NALFAs would enable the rapid implementation of specific therapeutic measures and inhibit further spread of pathogen.
In cooperation with the High‑Performance Center for Mass Personalization, researchers in the innovation field of Virus‑based Technologies have now developed a NALFA to detect herpes simplex virus 1 (HSV‑1) as proof of concept. To this end, the genomic DNA of the virus was specifically amplified by means of a polymerase chain reaction and modified for detection in an LFA. Here, modification of the genome target sequences and their hybridization with the immobilized and complementary capture DNA generates a color signal that indicates the presence of the specific pathogen (Fig. 1).
Based on these results, further developments are conceivable, including isothermal amplification of the pathogen genome as well as the parallel detection of several pathogens on one strip. The aim is to create a fast, device‑independent POCT for the detection of pathogens, which can be used in regions with poor medical infrastructure.
Further development for SARS-CoV-2 for the diagnosis of Covid-19
Thus, the test is also suitable for the rapid and reliable diagnosis of the novel coronavirus SARS-CoV-2. Such a rapid test would help to expand the diagnostic capacities and thus obtain more reliable data on the spread of Covid-19.